RxElite, Inc. (RXEI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
RxElite, Inc. (RXEI) trades at $0.00 with AI Score 65/100 (Grade B+). RxElite, Inc. Market cap: $1,483, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for RXEI: RXEI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RXEI against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
RXEI: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →RxElite, Inc. (RXEI) Healthcare & Pipeline Overview
RxElite, Inc. specializes in developing, producing, and commercializing generic prescription drugs, particularly sterile liquid dose offerings like ophthalmic solutions, respiratory inhalants, and injectables. As a subsidiary of Piramal Healthcare Ltd., it also manufactures active pharmaceutical ingredients (APIs) for a global client base, serving hospitals, wholesalers, and retail pharmacies across specialty markets.
What Is the Investment Thesis for RXEI?
RxElite, Inc. operates within the specialized generic pharmaceutical market, focusing on high-demand sterile liquid dose products and active pharmaceutical ingredient (API) manufacturing. The company's diverse portfolio, encompassing generic ophthalmic solutions, respiratory inhalants, and injectables, targets critical healthcare needs across institutional and retail channels. Strategic alliances with partners like Stason Pharmaceuticals and Alkem Laboratories enhance its market reach and development capabilities, while its role as an API manufacturer provides a diversified revenue stream across the US, Europe, and Asia. However, the company faces significant financial challenges, evidenced by a negative profit margin of -610.5% and a low gross margin of 5.1%. Its listing on the 'OTC Other' tier suggests higher risk due to potential limited disclosure and lower liquidity. Investors should evaluate RxElite's ability to achieve sustainable profitability and navigate regulatory complexities within the highly competitive generic drug sector, while also considering the strategic value derived from its specialized product focus and parent company affiliation.
Based on FMP financials and quantitative analysis
RXEI Key Highlights
- RxElite, Inc. reported a negative profit margin of -610.5%, indicating substantial unprofitability within its operations.
- The company maintains a gross margin of 5.1%, reflecting a narrow profit after accounting for the cost of goods sold.
- With a Beta of 6.40, RxElite, Inc. exhibits extremely high volatility relative to the broader market, suggesting significant price fluctuations.
- RxElite, Inc. operates with 47 employees, focusing on specialized generic drug development and API manufacturing.
- The company is a subsidiary of Piramal Healthcare Ltd., leveraging a larger corporate structure for its operations and strategic direction.
Who Are RXEI's Competitors?
RXEI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.05M | 64 |
| AVDL Avadel Pharmaceuticals plc | $21.64 | +0.00% | $2.12B | 64 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.34M | 63 |
| CAMRF Camurus AB (publ) | $60.00 | -1.66% | $3.60B | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RXEI's Key Strengths?
- Specialization in sterile liquid dose generic drugs, addressing niche and high-demand markets.
- Diverse product portfolio including ophthalmic, respiratory, and injectable medications.
- Dual revenue streams from finished drug products and active pharmaceutical ingredient (API) manufacturing.
- Extensive customer base across institutional, wholesale, retail, and outpatient sectors.
- Strategic alliances with established industry partners enhancing market reach and capabilities.
What Are RXEI's Weaknesses?
- Significant unprofitability with a negative profit margin of -610.5%.
- Low gross margin of 5.1%, indicating limited profitability from core sales.
- Listing on the 'OTC Other' tier, implying higher risk and potentially limited transparency.
- Unknown disclosure status, which can hinder investor due diligence.
- Operating as a subsidiary, which may limit independent strategic decision-making.
What Could Drive RXEI Stock Higher?
- Development and commercialization of new generic prescription drugs, particularly within its sterile liquid dose portfolio.
- Expansion of active pharmaceutical ingredient (API) manufacturing services to new clients across the United States, Europe, and Asia.
- Leveraging strategic alliances with partners like Stason Pharmaceuticals, Inc., Alkem Laboratories Limited, and Zach Systems S.p.A. to enhance market penetration and product development.
- Continued sales and distribution to its extensive customer base, including hospitals, wholesale distributors, and retail pharmacy chains.
What Are the Key Risks for RXEI?
- Financial-distress signal — its Altman Z-Score of -2.08 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Sustained unprofitability, as indicated by a negative profit margin of -610.5%, posing challenges to long-term financial viability.
- Operating on the 'OTC Other' tier, which typically implies higher risk due to limited disclosure, lower liquidity, and increased price volatility.
- Intense competition within the generic drug and API manufacturing sectors, leading to pricing pressures and market share erosion.
- Regulatory compliance challenges and the need for continuous adherence to evolving pharmaceutical industry standards.
- Dependence on strategic alliances, where changes in partner relationships or performance could impact business operations and growth opportunities.
What Are the Growth Opportunities for RXEI?
- Growth opportunity 1: Expanding Generic Sterile Liquid Dose Portfolio. RxElite, Inc. has a significant opportunity to expand its portfolio of generic ophthalmic solutions and sterile unit-dose respiratory inhalation products. The market for sterile liquid dose generics is driven by increasing demand for cost-effective alternatives to branded drugs, particularly in chronic conditions requiring long-term treatment. By developing and commercializing new generic versions of popular sterile liquid medications, RxElite can capture additional market share. This expansion could involve targeting new therapeutic areas within ophthalmology or respiratory care, or introducing new formulations that offer improved patient compliance or delivery mechanisms. The timeline for such expansion is ongoing, as product development and regulatory approvals are continuous processes in the pharmaceutical industry, with market sizes for these segments often valued in the billions globally.
- Growth opportunity 2: Capitalizing on the Injectable Medications Market. The market for generic injectable medications, especially those used in hospitals, outpatient surgery centers, and ambulatory care clinics, presents a robust growth avenue for RxElite. Injectables are critical for a wide range of medical treatments, and the demand for generic, cost-effective versions is consistently high among institutional clients seeking to manage healthcare costs. By focusing on developing and commercializing a broader array of generic injectable drugs, RxElite can deepen its penetration into its existing customer base of hospitals and group purchasing organizations. This strategy leverages the company's sterile manufacturing capabilities and existing distribution channels, offering a direct path to increased revenue. The market for generic injectables is substantial and continues to grow, driven by an aging population and increasing chronic disease prevalence.
- Growth opportunity 3: Growth in Active Pharmaceutical Ingredient (API) Manufacturing Services. RxElite's role as an API manufacturer for other pharmaceutical entities across the United States, Europe, and Asia represents a significant, ongoing growth opportunity. The global pharmaceutical industry increasingly relies on external API suppliers to manage supply chain complexities, reduce costs, and ensure a steady supply of raw materials. By expanding its API manufacturing capacity, diversifying its API product offerings, and attracting new pharmaceutical clients, RxElite can capitalize on this outsourcing trend. Strategic investments in R&D for new APIs or enhancing manufacturing efficiencies could strengthen its competitive advantage. The global API market is a multi-billion dollar industry, with continuous demand for high-quality, compliant ingredients, offering a stable and expanding revenue stream for RxElite.
- Growth opportunity 4: Leveraging Strategic Alliances for Market Penetration. RxElite's strategic alliances with industry partners such as Stason Pharmaceuticals, Inc., Alkem Laboratories Limited, and Zach Systems S.p.A. provide a crucial platform for growth. These partnerships can facilitate co-development of new generic products, access to new geographic markets, or enhanced manufacturing capabilities. By actively collaborating with these partners, RxElite can accelerate product launches, share development risks, and tap into established distribution networks that might otherwise be difficult to access independently. Strengthening and expanding these alliances, or forming new ones, can lead to increased product pipeline diversification and broader market reach, particularly in international markets where partners may have stronger local presence and regulatory expertise. The timeline for realizing benefits from alliances is ongoing, as they are continuous collaborative efforts.
- Growth opportunity 5: Penetration of Institutional and Outpatient Markets. RxElite's extensive customer base, which includes hospitals, hospital group purchasing organizations, national and regional wholesale distributors, major direct retail pharmacy chains, home healthcare providers, and outpatient surgery centers, offers continuous growth potential. By deepening relationships with these existing clients and expanding its reach to new ones, RxElite can increase sales volume for its current product lines and introduce new offerings. This involves targeted sales and marketing efforts, competitive pricing strategies, and ensuring robust supply chain reliability. The ongoing shift towards outpatient care and the persistent need for cost-effective medications in institutional settings provide a sustained demand environment. Expanding its presence within these critical healthcare segments, particularly with its specialized sterile liquid dose products, can drive consistent revenue growth.
What Opportunities Does RXEI Have?
- Growing global demand for affordable generic prescription drugs.
- Expansion into new therapeutic areas or geographic markets for sterile liquid dose products.
- Increased outsourcing trend in active pharmaceutical ingredient (API) manufacturing.
- Leveraging strategic alliances to co-develop new products or access new distribution channels.
- Capitalizing on the shift towards outpatient care and the need for cost-effective solutions in these settings.
What Threats Does RXEI Face?
- Intense competition and pricing pressure within the generic drug manufacturing industry.
- Stringent and evolving regulatory requirements for pharmaceutical products and APIs.
- Potential for R&D failures or delays in obtaining regulatory approvals for new generic drugs.
- Market perception and investor confidence challenges due to its OTC Other tier listing and financial performance.
- Dependence on key strategic alliances and potential risks associated with partnership dynamics.
What Are RXEI's Competitive Advantages?
- Specialization in sterile liquid dose generic drugs, a segment requiring specific manufacturing expertise and regulatory compliance.
- Dual business model encompassing both finished generic drug products and active pharmaceutical ingredient (API) manufacturing services.
- Established strategic alliances with industry partners like Stason Pharmaceuticals, Alkem Laboratories, and Zach Systems S.p.A.
- Diverse and extensive customer base spanning institutional, wholesale, retail, and outpatient healthcare sectors.
- Operating as a subsidiary of Piramal Healthcare Ltd., potentially benefiting from larger corporate resources and stability.
What Does RXEI Do?
RxElite, Inc. is a pharmaceutical company dedicated to the development, production, and commercialization of generic prescription drugs, with a strategic focus on specialty markets. The company's comprehensive product portfolio is centered around Sterile Liquid Dose offerings, which include a range of generic ophthalmic solutions available in both convenient unit-dose and multi-dose formats. Beyond eye care, RxElite also produces sterile unit-dose respiratory inhalation products, addressing critical needs in respiratory health, and various injectable medications vital for institutional healthcare settings. This diverse product array positions RxElite to cater to specific, high-demand segments within the generic pharmaceutical landscape. Operating through its subsidiaries, RxElite extends its capabilities beyond finished drug products by serving as a manufacturer of active pharmaceutical ingredients (APIs). This crucial service supports other pharmaceutical entities across significant global markets, including the United States, Europe, and Asia, highlighting its role in the broader pharmaceutical supply chain. The company's extensive customer base is a testament to its market reach and includes major institutional clients such as hospitals and hospital group purchasing organizations (GPOs), national and regional wholesale distributors, large direct retail pharmacy chains, home healthcare providers, and various outpatient surgery centers and ambulatory care clinics. This broad distribution network ensures its products reach a wide array of healthcare providers and patients. Headquartered in Meridian, Idaho, RxElite Inc. maintains strategic alliances with key industry partners, including Stason Pharmaceuticals, Inc., Alkem Laboratories Limited, and Zach Systems S.p.A. These collaborations are instrumental in enhancing its product development, manufacturing capabilities, and market penetration. As a subsidiary of Piramal Healthcare Ltd., RxElite benefits from the resources and strategic direction of a larger parent organization, further solidifying its operational framework and market presence within the competitive generic drug manufacturing industry.
What Products and Services Does RXEI Offer?
- Develops generic prescription drugs for specialty markets.
- Produces sterile liquid dose ophthalmic solutions in unit-dose and multi-dose formats.
- Manufactures sterile unit-dose respiratory inhalation products.
- Creates various injectable medications for institutional use.
- Serves as a manufacturer of active pharmaceutical ingredients (APIs) for other pharmaceutical companies.
- Distributes products to hospitals, wholesale distributors, retail pharmacies, and outpatient centers.
- Maintains strategic alliances with pharmaceutical partners like Stason, Alkem, and Zach Systems.
- Operates as a subsidiary of Piramal Healthcare Ltd.
How Does RXEI Make Money?
- Research, develop, and commercialize generic prescription drugs, focusing on specialty markets.
- Manufacture and sell a diverse portfolio of sterile liquid dose products, including ophthalmic, respiratory, and injectable medications.
- Provide active pharmaceutical ingredient (API) manufacturing services to other pharmaceutical entities globally.
- Generate revenue through sales to a broad customer base including institutional clients, wholesale distributors, and retail pharmacy chains.
What Industry Does RXEI Operate In?
RxElite, Inc. is positioned within the dynamic and highly competitive Drug Manufacturers - Specialty & Generic industry. This sector is characterized by intense price competition, stringent regulatory oversight, and a continuous need for product development and differentiation. RxElite's specialization in sterile liquid dose offerings, such as generic ophthalmic solutions, respiratory inhalants, and injectables, allows it to target niche markets within the broader generic landscape, where demand for quality and specific delivery formats is high. The company's role as an active pharmaceutical ingredient (API) manufacturer also places it within the critical upstream segment of the pharmaceutical supply chain, serving other drug developers globally. Market trends indicate a growing demand for affordable generic alternatives and a rising need for specialized, sterile formulations, particularly in institutional settings. However, the industry also faces pressures from patent expirations, increasing R&D costs for new generics, and evolving global regulatory standards, requiring companies like RxElite to maintain agility and strategic partnerships to sustain market relevance.
Who Are RXEI's Key Customers?
- Hospitals and hospital group purchasing organizations (GPOs).
- National and regional wholesale distributors.
- Major direct retail pharmacy chains.
- Home healthcare providers.
- Outpatient surgery centers and ambulatory care clinics.
Company Profile
RxElite, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Meridian, US. The company is led by CEO Richard Tener. RXEI has traded publicly since 2020.
How RxElite, Inc. Is Valued
RxElite, Inc. carries a market capitalization of 1K, placing it in the micro-cap category. Relative to its peer group, RXEI's quantitative score of 65/100 is roughly in line with the peer average of 67/100.
Key Financial Metrics
Return on assets is -80.7%, showing how much profit it generates from its asset base. A current ratio of 2.59 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 1/9Financial Health
RxElite, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.08 places it in the distress zone, a signal of elevated financial risk.
Net buyingInsider Activity
The most recent 7 insider filings for RxElite, Inc. break down as 2 sales and 5 purchases. On net that is roughly 1.8M shares acquired (about $240K) — insiders putting money in tends to read as conviction.
RXEI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialization in sterile liquid dose generic drugs, addressing niche and high-demand markets.
- Diverse product portfolio including ophthalmic, respiratory, and injectable medications.
- Dual revenue streams from finished drug products and active pharmaceutical ingredient (API) manufacturing.
- Extensive customer base across institutional, wholesale, retail, and outpatient sectors.
Bear Case
- Significant unprofitability with a negative profit margin of -610.5%.
- Low gross margin of 5.1%, indicating limited profitability from core sales.
- Listing on the 'OTC Other' tier, implying higher risk and potentially limited transparency.
- Unknown disclosure status, which can hinder investor due diligence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
RXEI Latest News
No recent news available for RXEI.
RXEI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RXEI.
Price Targets
Wall Street price target analysis for RXEI.
RXEI MoonshotScore
What does this score mean?
The MoonshotScore rates RXEI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Richard Tener
Chief Executive Officer
Richard Tener serves as a key leader at RxElite, Inc., where he is responsible for managing the company's 47 employees. Details regarding his specific educational background, prior executive roles, or a comprehensive career history before joining RxElite, Inc. are not explicitly provided in the available source data. His role involves overseeing the operational and strategic direction of the pharmaceutical company, which specializes in generic prescription drugs and API manufacturing.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Mr. Tener's leadership are not detailed in the provided information. His tenure is characterized by the ongoing management of RxElite, Inc.'s operations, focusing on the development, production, and commercialization of its diverse portfolio of generic prescription drugs and its active pharmaceutical ingredient manufacturing services.
RXEI OTC Market Information
RxElite, Inc. trades on the 'OTC Other' tier of the over-the-counter market. This tier is typically for companies that do not meet the minimum listing requirements for exchanges like the NYSE or NASDAQ, or even higher OTC tiers like OTCQX or OTCQB. Companies on the 'OTC Other' tier often have limited public disclosure, which can make it challenging for investors to access comprehensive financial and operational information. In contrast, major exchanges impose stringent reporting, governance, and financial standards, offering greater transparency and investor protection. The 'OTC Other' designation generally implies a higher risk profile due to less oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure and transparency, making comprehensive due diligence challenging.
- Significantly lower trading volume and wider bid-ask spreads, leading to reduced liquidity.
- Increased price volatility due to low trading activity and fewer market participants.
- Potential for limited access to capital markets for financing future operations.
- Negative market perception and investor confidence associated with OTC Other tier listing.
- Verify the availability and content of any financial statements or regulatory filings.
- Thoroughly research the company's business operations, product pipeline, and market position.
- Assess the management team's experience and track record, if available.
- Investigate any legal or regulatory issues the company may be facing.
- Evaluate the company's strategic alliances and their impact on future prospects.
- Understand the competitive landscape within its specific generic drug and API markets.
- Consider the implications of its subsidiary status under Piramal Healthcare Ltd.
- Operating as a subsidiary of Piramal Healthcare Ltd., a larger pharmaceutical entity.
- Maintains strategic alliances with recognized industry partners like Stason Pharmaceuticals and Alkem Laboratories.
- Has a physical headquarters in Meridian, US, and a stated employee count of 47.
- Serves a diverse and established customer base including hospitals, wholesalers, and retail chains.
- Specializes in a tangible and regulated industry: generic prescription drugs and API manufacturing.
Common Questions About RXEI (Healthcare)
What is RxElite, Inc.'s primary business model in the pharmaceutical sector?
RxElite, Inc. operates as a specialized pharmaceutical company primarily focused on the development, production, and commercialization of generic prescription drugs. Its core business model involves manufacturing sterile liquid dose products, including generic ophthalmic solutions in unit-dose and multi-dose formats, sterile unit-dose respiratory inhalation products, and various injectable medications. Additionally, through its subsidiaries, RxElite functions as a manufacturer of active pharmaceutical ingredients (APIs) for other pharmaceutical companies across the United States, Europe, and Asia. Revenue is generated from sales to a broad customer base, including hospitals, wholesale distributors, retail pharmacy chains, and outpatient centers.
How does RxElite, Inc.'s position on the OTC Other tier impact investors?
RxElite, Inc.'s listing on the 'OTC Other' tier signifies a higher risk profile for investors compared to companies trading on major exchanges like the NYSE or NASDAQ. This tier is characterized by less stringent disclosure requirements, which means public financial and operational information may be limited or unavailable, as indicated by its 'Unknown' disclosure status. Furthermore, stocks on this tier typically experience significantly lower trading volume and wider bid-ask spreads, leading to reduced liquidity. This can make it challenging to execute trades efficiently and may contribute to higher price volatility, requiring investors to conduct extensive due diligence.
What are the key financial characteristics of RxElite, Inc. that investors may want to evaluate?
Investors evaluating RxElite, Inc. should note several key financial characteristics. The company reports a negative profit margin of -610.5%, indicating significant unprofitability. Its gross margin stands at 5.1%, suggesting that after the cost of goods sold, very little revenue remains to cover operating expenses. The market capitalization is stated as $0.00 billion, which implies a very small or negligible market value. A high Beta of 6.40 suggests extreme volatility relative to the broader market. These metrics collectively point to a company facing substantial financial challenges, requiring careful consideration of its path to sustainable profitability.
What are the key factors to evaluate for RXEI?
RxElite, Inc. (RXEI) holds an AI score of 65/100 (moderate). Not financial advice.
How frequently does RXEI data refresh on this page?
RXEI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RXEI's recent stock price performance?
RxElite, Inc. (RXEI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in sterile liquid dose generic drugs, addressing niche and high-demand markets. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RXEI overvalued or undervalued right now?
Valuing RxElite, Inc. (RXEI) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying RXEI?
Before investing in RxElite, Inc. (RXEI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited to provided source data.
- Specific market sizes, timelines, and detailed financial breakdowns beyond provided metrics are not available in the source data.
- CEO's background and track record details are limited in the source data.